Sep 2026· Journal of Stroke & Cerebrovascular Diseases· Vol 35, pp.
108748
· 0 citations
Medicine
TL;DR
This study suggests that CMI may serve as a potential biomarker associated with stroke incidence and mortality, and indicates that CMI could have utility in clinical settings for the identification of high-risk populations, although further validation is needed.
Abstract
Background
While the cardiometabolic index (CMI) has emerged as a potential stroke predictor, its utility across diverse populations and specific clinical contexts remains underexplored. This study aims to bridge these methodological and clinical knowledge gaps using large-scale, multi-ethnic cohorts.
Methods
Leveraging data from the UK Biobank (n=413,686) and NHANES (n=40,607), we employed multivariate Cox proportional hazards regression to evaluate the associations between CMI and incident ischemic/hemorrhagic stroke, as well as cerebrovascular mortality. Restricted cubic splines (RCS) were utilized to characterize potential non-linear dose-response relationships.
Results
RCS analysis demonstrated a non-linear association between CMI and both ischemic and hemorrhagic stroke. In fully adjusted models, each unit increase in CMI was associated with elevated stroke and mortality risk: 24% higher risk of ischemic stroke (HR = 1.24, 95% CI: 1.21-1.28) and a 11% increased risk of cerebrovascular mortality (HR = 1.11, 95% CI: 1.01-1.21). Notably, interaction analyses confirmed joint modifying effects, indicating that genetic susceptibility and metabolic dysfunction collectively amplify stroke risk. Subgroup analyses revealed that the association between CMI and stroke was stronger in younger individuals and females.
Conclusions
Our study suggests that CMI may serve as a potential biomarker associated with stroke incidence and mortality. These observations indicate that CMI could have utility in clinical settings for the identification of high-risk populations, although further validation is needed. To better understand the clinical applicability of these findings, future research should focus on the development of integrated clinical prediction tools and comprehensive health economic evaluations to assess the feasibility of CMI-based screening strategies.
BACKGROUND
The cardiometabolic index (CMI), a composite marker derived from the product of waist-to-height ratio and triglyceride-to- high-density lipoprotein cholesterol ratio, has emerged as a potential indicator of metabolic risk. However, the prognostic value of the CMI across diverse populations and the continuum...
Zhen-Yu Liu, Zhi-Xin Li, Si-Yan Huo et al.· Heart, Lung and Circulation· 0 citations
The findings suggest that the vascular relevance of the CMI may vary according to the underlying glucose metabolic status and support its potential role as a marker of cardiometabolic dysfunction.
Meng Li, Yong-Bo Yu, Xuan Chen et al.· International Journal of End...· 0 citations
Background Cardiometabolic multimorbidity (CMM) is an increasing public health challenge in aging populations. The cholesterol–high-density lipoprotein–glucose (CHG) index is an emerging metabolic marker, but its association with prevalent CMM has not been sufficiently evaluated across community and hospitalized popula...
Ze-Xu Cui, Tian-Hao Lan, Min-Chin Lu et al.· Frontiers in Public Health· 0 citations
Cardiometabolic multimorbidity (CMM), defined as the coexistence of at least two cardiometabolic diseases (CMDs, including myocardial infarction, diabetes, and stroke), has been established as an important risk factor for adverse cardiovascular outcomes [1-2]. However, the differential impact of varying CMM burde...
J. Gao, Y.-H. Wang, Y.-Q. Li et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.